STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co - MRK STOCK NEWS

Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.

Merck & Co. (NYSE: MRK) is a global pharmaceutical leader with a 350-year legacy of medical innovation. This news hub provides investors and healthcare professionals with direct access to official announcements, financial disclosures, and research developments shaping the company's trajectory.

Track MRK's latest regulatory milestones, clinical trial results, and strategic partnerships through verified press releases and curated analysis. Our repository includes earnings call transcripts, FDA approval updates, and global health initiatives—all organized for efficient research and due diligence.

Key updates on therapeutic advancements in oncology, vaccines, and infectious diseases are maintained alongside financial performance data. Bookmark this page for real-time access to Merck's corporate communications and market-moving developments in the pharmaceutical sector.

News

Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery

Rhea-AI Summary
Merck's phase 3 trial of KEYTRUDA shows significant improvement in disease-free survival for patients with localized MIUC and locally advanced urothelial carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
clinical trial
-
News

Merck to Hold Third-Quarter 2023 Sales and Earnings Conference Call Oct. 26

Rhea-AI Summary
Merck to hold Q3 2023 sales and earnings conference call on Oct. 26.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
earnings
-
News

Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)

Rhea-AI Summary
Merck's new Biologics License Application for sotatercept, an investigational activin signaling inhibitor, has been accepted for priority review by the FDA for the treatment of adult patients with pulmonary arterial hypertension (PAH). The Prescription Drug User Fee Act (PDUFA) date is set for March 26, 2024. Results from the Phase 3 STELLAR trial showed statistically significant and clinically meaningful improvement in 6-minute walk distance (6MWD) and secondary outcome measures. This could potentially transform the treatment of PAH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
News

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer

Rhea-AI Summary
Merck and Eisai provide updates on Phase 3 trials for KEYTRUDA plus LENVIMA in metastatic non-small cell lung cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
clinical trial
-
News

Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Rhea-AI Summary
Merck announces positive Phase 3 results for KEYTRUDA and Padcev combination in urothelial carcinoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
clinical trial
-
News

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Rhea-AI Summary
Merck's supplemental Biologics License Application for KEYTRUDA in combination with radiotherapy and chemotherapy for cervical cancer has been accepted for priority review by the FDA. If approved, this would be Merck's third indication in cervical cancer and first in an earlier stage of the disease. The FDA has set a target action date of January 20, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
none
News

FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

Rhea-AI Summary
Merck's supplemental new drug application for WELIREG, an oral HIF-2α inhibitor, has been accepted by the FDA for the treatment of advanced renal cell carcinoma (RCC) following previous therapies. The application has been granted priority review, and the FDA has set a target action date of January 17, 2024. Data from the LITESPARK-005 trial showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to everolimus, as well as a significant improvement in objective response rate (ORR). WELIREG is currently approved for the treatment of VHL disease. This development program includes four Phase 3 trials in RCC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
clinical trial
-
News

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

Rhea-AI Summary
Merck's anti-PD-1 therapy, KEYTRUDA, receives positive opinion for adjuvant treatment of NSCLC in Europe
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
-
News

Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)

Rhea-AI Summary
Merck presents new analyses of sotatercept for the treatment of pulmonary arterial hypertension (PAH) at ERS International Congress 2023. Exploratory analysis shows that treatment with sotatercept improves right heart size and function. Primary efficacy results from the STELLAR trial demonstrate significant improvement in 6-minute walk distance. SOTERIA study shows long-term safety and efficacy of sotatercept. Applications for regulatory approval of sotatercept have been submitted. Positive potential for sotatercept to transform the treatment of PAH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
none
News

European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older

Rhea-AI Summary
Merck's ERVEBO receives expanded approval from the European Commission for immunization against Ebola Virus Disease caused by Zaire ebolavirus in individuals 1 year of age or older. The vaccine was previously approved for use in individuals 18 years of age or older. Merck has also established a global Ebola vaccine stockpile with UNICEF to support future outbreak preparedness and response efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
none
Stock MRK logo
Merck & Co

NYSE:MRK

MRK Rankings

#40 Ranked by Market Cap
#893 Ranked by Dividends

MRK Stock Data

199.22B
2.51B
0.07%
80.45%
1.62%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
KENILWORTH